The 'standard of care' is an interesting concept and one that is, to varying degrees, dictated not by scientific data but by the potentials for legal ramifications. The 'standard of care' can be equated to the column on the pantheon: once built, it is very difficult to tear down or modify.
Alternative Pharmacological Approaches to Cataract Surgery
The standard of care as indicated by the American Academy of Ophthalmology (AAO) post-cataract surgery includes an antimicrobial, a topical steroid, and topical NSAIDs. 3 The regimen, however, varies among ophthalmologists because of a lack of published data that establishes the optimal regimen -therefore, it is the decision of individual ophthalmologists to employ a regimen best suited to their cataract patients. Studies have shown the importance of antimicrobial prophylaxis in reducing ocular infection and endophthalmitis with the use of the newer generation of fluoroquinolones 5, 6 along with the usage of topical corticosteroids and NSAIDs to reduce and prevent anterior chamber inflammation and macular edema, respectively. 4, 7 More recently, collaboration among ophthalmologists raised the issue relating to pre-operative antimicrobial therapy. 8 Sterilizing and suppression of the microbial flora pre-operatively have been shown to decrease the risk of post-operative infection. Many methodologies are used to sterilize the surgical site, which include iodine tincture and/or pre-operative topical antimicrobial administration.
Studies have shown the validity of pre-treatment in reducing endophthalmitis. More recently, the European Society of Cataract and Refractive Surgery (ESCRS) conducted a long-term, prospective, and retrospective study to evaluate the validity of administering an antimicrobial prior to surgery in reducing the incidence of endophthalmitis. 9 This study and others demonstrated the incidence of endophthalmitis was not statistically different between those receiving pre-treatment and those not receiving pre-treatment. This is a landmark finding since the current ophthalmic teaching indicates the need for pre-operative treatment. 10 Post-operative antimicrobial therapy is still indicated; however, the question is "Should we pre-treat all cataracts with an antimicrobial and start topical steroids post-surgery?"
This debate will persist among ophthalmologists for some time.
European Society of Cataract and Refractive Surgery Endophthalmitis Study
The ESCRS endophthalmitis study was a multicenter, double-blind, placebo-controlled, partially masked randomized study to assess the clinical effectiveness of using intracameral cefuroxime with or without perioperative topical levofloxacin for the prevention of endophthalmitis after routine phacoemulsification (see Table 1 ). 9, 11 Since the ESCRS study, intracameral antibiotics have become the standard in Europe. However, while this has not been widely adapted in North America their use is increasing. The ESCRS study compared the outcomes among four treatment groups, including a control group and patients receiving frequently applied topical fluoroquinolone drops (levofloxacin 0.5 %) -as well as patients receiving an intracameral injection of cefuroxime 1 mg. 9 An independent study, that is, not directly related or associated with the ESCRS study, reproduced the identical fluoroquinolone dosing regimen used in the ESCRS study. Investigators measured aqueous humor antibiotic levels over a 90 minute post-dose period. The regimen of two pre-operative drops (one each at 30 and 60 minutes pre-operatively) plus three pulsed drops (one every five minutes at the end of surgery)
produced the highest reported levels of fluoroquinolone in aqueous humor (4.4 μg/ml). 12 This independent study was able to demonstrate that, in contrast to topical drops, the intracameral injection (1 mg or 1,000 μg cefuroxime in this case) was capable of delivering a much higher dose instantaneously to the aqueous humor, since topical agents must first diffuse through the cornea. 12 
Intracameral Cefuroxime
Patients were randomized into four groups. Two of the four groups were treated with intracameral cefuroxime (1 mg in 0.1 ml normal saline solution) at the end of surgery. Two groups (one treated with intracameral cefuroxime, one untreated) received peri-operative topical levofloxacin 0.5 % in a standard regimen. The study was masked for levofloxacin, but not for intracameral cefuroxime. All groups also received povidone-iodine 5 % pre-operatively and topical levofloxacin 0.5 % four times daily post-operatively for six days.
9,13
The incidence of endophthalmitis in the groups not receiving intracameral cefuroxime was statistically significantly higher than that in the groups receiving intracameral cefuroxime. Twenty-nine cases were diagnosed with post-operative endophthalmitis, of which 20 were infectious in nature. Five of the 29 reported cases occurred in groups receiving intracameral cefuroxime. Of these five cases, three had a
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Intracameral Cefazolin
Two observational studies showed a statistically significant reduction in the rate of post-operative endophthalmitis with the use of intracameral cefazolin plus topical antibiotics compared with topical antibiotics alone.
No toxic effects or anaphylactic reactions were reported in either study.
18,19

Economic Considerations
Sharifi et al. determined the cost-effectiveness from a societal perspective in the US of different antibiotic regimens for the prevention of endophthalmitis after cataract surgery (see Table 2 ). 20 The modes of administration for the antibiotics were intracameral (cefuroxime or moxifloxacin), topical (sulfacetamide, polymyxin/trimethoprim, ciprofloxacin, ofloxacin, moxifloxacin, or gatifloxacin), and subconjunctival (gentamicin or cefazolin). A combination regimen of intracameral cefuroxime, subconjunctival gentamicin, subconjunctival cefazolin, and topical sulfacetamide was also assessed. The risk of endophthalmitis in the absence of any intervention was estimated to be 0.247 %. 20 The risk of endophthalmitis when intracameral cefuroxime or the four antibiotic combination regimen was used was estimated to be 0.045 %. Assuming a 100 % prevention of endophthalmitis, the cost per case of endophthalmitis was estimated to be $3,793. The productivity losses caused by endophthalmitis were excluded from the cost analysis. 
Topical Steroid-Indicated or Not Indicated
The use of a topical steroid in the post-operative period is also under discussion. At the start of the twenty-first century, the idea that topical steroids would no longer be needed in uncomplicated cataract surgery would have been a very radical concept, if not downright inconceivable.
Today, with the advancements in surgical techniques, e.g., small incision, surgical technologies (torsional phacoemulsification and femtosecond), and the more efficacious NSAIDs, the concept of 'no steroids' is not as radical. The complications [21] [22] [23] [24] [25] [26] and benefits, 4,26-30 e.g., controlling and preventing macular edema, associated with topical steroids are well documented. The initial indication for steroid usage post cataract surgery was secondary to the inflammation. This inflammation was caused by the type of lens implanted, the quality of the lenses in the earlier years, and the methodology of extracting a cataractous lens. IOLs today are of higher quality, have better quality control during production, better surgical techniques, better surgical equipment, and require a shorter surgical time. Collectively, these factors minimize the degree of inflammation. Yet, ophthalmologists, on the whole, persist in prescribing topical steroids.
The reasons for the persistence of steroid usage are multifactorial, but two key factors appear to be consistent over the years: unpredictability and expectation. The unpredictability of how one patient will respond to surgery compared to the next, even when the surgeon performs the same procedure on similar patients with no significant comorbidities, is a factor. Another factor is patient's expectations-realistic or unrealistic.
Patients today are better informed than patients 20 years ago and this is a direct result of technology, e.g., the computer and the Internet.
One option is to use what are termed 'safe steroids.' These steroids, e.g., loteprednol etabonate ophthalmic suspension, are potent, efficacious, and have fewer side effects when compared to prednisolone acetate and other potent steroids. 30 Difluprednate ophthalmic emulsification 0.05 % was approved by the US Food and Drug Administration (FDA) and indicated for the treatment of inflammation and pain associated with ocular surgery. The major benefit associated with difluprednate is its twice-a-day dosing frequency.
The twice-daily doses enhance therapeutic compliance. Another benefit is dose uniformity, i.e. dosing concentration, which was predictable compared to that of other topical steroids for which the drop concentrations were highly variable. 32 However, reports have indicated that the use of difluprednate is associated with significant IOP elevation and the drug is expensive. demonstrated that NSAIDs alone were efficacious in controlling anterior segment inflammation. 36 The study also demonstrated that topical NSAIDs were equally efficacious as topical steroids in preventing the development of cystoid macular edema both, clinically and by OCT. 36 One real drawback to NSAIDs is that, although all the NSAIDs are covered by insurance companies, the co-pay tier for the respective NSAIDs is dependent on the state and county the patients reside in, which can translate into a costly endeavor for patients on fixed incomes.
The Future
The future of pharmacotherapy after cataract surgery is a work-in process and open for discussion and further research. Antimicrobial prophylaxis use pre-operatively to decrease or prevent endophthalmitis
Conclusion
The paradigm in pharmacotherapy post-uncomplicated cataract surgery has deviated from the 'norm' as indicated by the AAO Preferred Practice
Pattern. Intra-operative intracameral injection of cefuroxime and cefazolin has been widely employed in Europe since the ESCRS study and has begun to gain a foot hold in the US. Intracameral antibiotics have been shown to decrease the incidence of endophthalmitis and macular edema, and to be cost-effective.
Topical steroids, e.g., prednisolone acetate 1 %, are commonly prescribed after cataract surgery. Studies have shown the risks associated with topical steroids and a recent study demonstrated that topical steroid use is not necessary in controlling inflammation after cataract surgery.
Topical NSAIDs in uncomplicated cataract surgery are indicated and should be a mainstay because they provide an anti-inflammatory property that contributes to both decreasing and preventing cystoid macular edema. Non-steroidals also function in pain control without the side effects associated with narcotics or opioids, e.g., dependency.
The author believes that the pharmacological approach based on the patient's ocular and medical history should be tailored to each patient who undergoes cataract surgery, as opposed to a general 'standardized' treatment for all patients. Tailoring the treatment will increase compliance and decrease the cost to the patients. n
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